The new ST Genesia analyser is designed to automate and standardize results for thrombin generation. For laboratories, this is a significant step forward for assisting with assessment of thrombotic and hemorrhagic risks in patients.
ST Genesia is an automated analyser, based on the same principles as the CAT system, which measures thrombin generation. Designed to support clinical applications in the lab, the key difference between systems is that CAT’s main purpose is for research and development.
ST Genesia aims at standardizing and automating the thrombin generation test in order to make it widely accessible and available for use in in-vitro diagnostics (IVD). ST Genesia is designed to add to the information usually provided by routine tests (TP, TCA, etc.) or specialized tests (Anti-Xa, ECA) and offer an improved assessment of thrombotic and hemorrhagic risks.
A range of reagents specifically developed for ST Genesia is available including STG-ThromboScreen for thrombin generation assessment in patients who are likely to suffer from thrombophilia; STG-BleedScreen for thrombin generation assessment in patients with bleeding risk, such as hemophiliacs; STG-DrugScreen for assessment of the effect of anticoagulants on treated patients, which could be useful for people at risk of drug accumulation (impaired renal function, people over 75, etc.).

Read more

Monoclonal antibodies (mAb) are important components of CE-marked IVD reagents used in diagnosis of diseases and follow-up of treatment. DIAsource Immunoassays, a BioVendor group company, recently announced the launch of 13 new antibodies for IVD applications: Adiponectin, FABP4, COMP, NT-ProANP, Uromodulin, Soluble Transferrin Receptor, Placental Protein 13, Cathepsin K and Procalcitonin antibodies are now available and offered to the IVD providers for development of Immunoassays. This follows the launches of novel Vitamin D conjugates, Vitamin D dissociation buffers, and antibodies against ACTH, PTH, IGF-1, Testosterone and Progesterone. All these antibodies were developed with special focus on sensitivity, selectivity and stability to ensure long-term supply. They are produced and fully automatically purified under strict ISO 9001 – ISO 13485 conditions. Products are available in purified unconjugated format. Large scale productions can be guaranteed in state-of-the-art facilities. DIAsource is continuously expanding its product portfolio with niche, high valued parameters and these new launches consolidate its actual position on the market, with an enlarged portfolio of proven and performing antibodies for IVD providers.
Read more

TRIMERO Diagnostics offers IVD CE urinary assays of low molecular weight proteins, by nephelometry or turbidimetry, for the assessment of renal tubular function:

• Retinol-Binding Protein (RBP)
• Alpha-1 Microglobulin (α1μ)
• Cystatin C (CysC)
• Beta-2 Microglobulin (β2μ)
• KLoneus® Kappa and Lambda Free Light Chains (FLC)
• Kappa and Lambda (B&F) Light Chains

These assays, specifically designed for their use on urine samples, are available for the nephelometers and the most popular clinical chemistry analyzers present in the market.
Other TRIMERO’s available nephelometric and turbidimetric assays include:
Serum Amyloid A (SAA), IgD Immunoglobulins, Soluble Transferrin Receptor (sTfR), Hemopexin, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.
Read more

HER The TSQ Altis MD Series mass spectrometer offers enhanced sensitivity for demanding quantitative analyses together with speed and robustness. With superb analytical performance, this platform features maximum usability and is powered by Thermo Scientific TraceFinder LDT Software, which provides a workflow-oriented approach to robust, reliable, high-throughput quantitation. The instrument’s ultimate quantitative performance leverages enhanced Thermo Scientific Active Ion Management (AIM+) technology. QR5 segmented hyperbolic-surface quadrupoles deliver best-in-class sensitivity, consistency, and reproducibility, while fast, selected-reaction monitoring enables robust quantitation of more compounds faster. Features include automated compound optimization and intuitive instrument interface as well as optional bi-directional LIS connection available with B-link.
The TSQ Altis MD Series mass spectrometer is intended to identify and quantify inorganic and organic compounds in human specimens for in vitro diagnostic use only by trained, qualified laboratory personnel. It will be used by clinical diagnostic laboratories as a component of a laboratory developed test (LDT) method or workflow.
Read more

Siemens Healthineers recently announced the new RAPIDPoint 500e blood gas system, their latest
solution in critical point-of-care testing. The new system generates blood gas, electrolyte  and metabolyte results used to diagnose and monitor critically ill patients typically in the intensive care unit, operating room or emergency room. The RAPIDPoint 500e blood gas system is available now in all countries requiring the CE mark. Developed with extensive customer feedback, the system is designed to elevate confidence in patient results with Integri-sense technology, streamline workflow with improved simplicity and raise the bar in data security. Cybersecurity is becoming a key operational factor. Health-care providers must protect confidential operator and patient information.
The RAPIDPoint 500e blood gas system incorporates Integri-sense technology, a comprehensive series of automated functional checks designed to deliver accurate test results at the point-of-care. Integri-sense technology combines three levels of automatic quality control (AutomaticQC), multiple calibration routines and advanced software algorithms to generate reliable and clinically actionable test results. It also integrates seamlessly into hospital networks with the Siemens Healthineers Point of Care Ecosystem which offers convenient, remote management of operators and devices located across multiple sites.
Read more